{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    45
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_1",
        "affectedSection": "Sections 3.1.1, 3.1.1.1, 4.1, 6, 6.1, 9.5",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Increase in patient sample size to ensure adequate power for the primary endpoint."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_1",
        "affectedSection": "Section 2.6",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Addition of language allowing for exploratory substudies."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_1",
        "affectedSection": "Section 3.1.2 and Appendix 1",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarification of procedures for missed PK, PD, or ADA samples."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_1",
        "affectedSection": "Section 4.3.3",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Update to IMP transit temperature monitoring requirements."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_1",
        "affectedSection": "Section 5.4.1",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Update to Medical Monitors and Emergency Medical Contacts."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_1",
        "reasonText": "Mitigate loss of patients and data due to extenuating circumstances such as the COVID-19 pandemic.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_1",
        "reasonText": "Ensure adequate power for the primary efficacy endpoint analyses.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_1",
        "reasonText": "Improve clarity and consistency of protocol instructions and administrative details.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_1",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.1.1",
        "beforeText": "Not specified",
        "afterText": "Increased sample size",
        "summary": "Sample size increased to mitigate impact of protocol deviations and data loss."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_1",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "2.6",
        "beforeText": "Not present",
        "afterText": "Language to allow the Sponsor to propose exploratory substudies associated with protocol GR41984",
        "summary": "Added provision for exploratory substudies."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_1",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.1.2",
        "beforeText": "Not specified",
        "afterText": "Missed mandatory pharmacokinetic, pharmacodynamic, or anti-drug antibody samples may be obtained at the next scheduled visit",
        "summary": "Clarified handling of missed laboratory samples."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_1",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.3.3",
        "beforeText": "Not specified",
        "afterText": "Sites can confirm appropriate temperature conditions via time monitoring or temperature monitoring",
        "summary": "Updated IMP transit monitoring options."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_1",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.4.3.1",
        "beforeText": "Not specified",
        "afterText": "Informed Consent Form will instruct female patients to inform the investigator if they become pregnant",
        "summary": "Added pregnancy notification instruction for female patients."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 3,
      "changeCount": 5
    }
  }
}